These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29523784)

  • 21. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
    Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
    Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
    Liu Y; Zhu C; Tang L; Chen Q; Guan N; Xu K; Guan X
    Int J Biol Sci; 2021; 17(1):178-187. PubMed ID: 33390842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
    Kessler JD; Kahle KT; Sun T; Meerbrey KL; Schlabach MR; Schmitt EM; Skinner SO; Xu Q; Li MZ; Hartman ZC; Rao M; Yu P; Dominguez-Vidana R; Liang AC; Solimini NL; Bernardi RJ; Yu B; Hsu T; Golding I; Luo J; Osborne CK; Creighton CJ; Hilsenbeck SG; Schiff R; Shaw CA; Elledge SJ; Westbrook TF
    Science; 2012 Jan; 335(6066):348-53. PubMed ID: 22157079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
    Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
    Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.
    Sullivan DK; Deutzmann A; Yarbrough J; Krishnan MS; Gouw AM; Bellovin DI; Adam SJ; Liefwalker DF; Dhanasekaran R; Felsher DW
    Oncogene; 2022 Nov; 41(45):4960-4970. PubMed ID: 36207533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis.
    Yue M; Jiang J; Gao P; Liu H; Qing G
    Cell Rep; 2017 Dec; 21(13):3819-3832. PubMed ID: 29281830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC activation is a hallmark of cancer initiation and maintenance.
    Gabay M; Li Y; Felsher DW
    Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developmental context determines latency of MYC-induced tumorigenesis.
    Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
    PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triterpene Acid (
    Choi HS; Kim SL; Kim JH; Deng HY; Yun BS; Lee DS
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer.
    Lancho O; Herranz D
    Trends Cancer; 2018 Dec; 4(12):810-822. PubMed ID: 30470303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.
    Cho MH; Park JH; Choi HJ; Park MK; Won HY; Park YJ; Lee CH; Oh SH; Song YS; Kim HS; Oh YH; Lee JY; Kong G
    Nat Commun; 2015 Jul; 6():7821. PubMed ID: 26199140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYC activity at enhancers drives prognostic transcriptional programs through an epigenetic switch.
    Jakobsen ST; Jensen RAM; Madsen MS; Ravnsborg T; Vaagenso CS; Siersbæk MS; Einarsson H; Andersson R; Jensen ON; Siersbæk R
    Nat Genet; 2024 Apr; 56(4):663-674. PubMed ID: 38454021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse.
    Filipponi D; Emelyanov A; Muller J; Molina C; Nichols J; Bulavin DV
    Mol Cell; 2019 May; 74(4):651-663.e8. PubMed ID: 30954402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.
    Nair R; Roden DL; Teo WS; McFarland A; Junankar S; Ye S; Nguyen A; Yang J; Nikolic I; Hui M; Morey A; Shah J; Pfefferle AD; Usary J; Selinger C; Baker LA; Armstrong N; Cowley MJ; Naylor MJ; Ormandy CJ; Lakhani SR; Herschkowitz JI; Perou CM; Kaplan W; O'Toole SA; Swarbrick A
    Oncogene; 2014 Jul; 33(30):3992-4002. PubMed ID: 24056965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.
    Ahmadiyeh N; Pomerantz MM; Grisanzio C; Herman P; Jia L; Almendro V; He HH; Brown M; Liu XS; Davis M; Caswell JL; Beckwith CA; Hills A; Macconaill L; Coetzee GA; Regan MM; Freedman ML
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9742-6. PubMed ID: 20453196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis.
    Carroll PA; Diolaiti D; McFerrin L; Gu H; Djukovic D; Du J; Cheng PF; Anderson S; Ulrich M; Hurley JB; Raftery D; Ayer DE; Eisenman RN
    Cancer Cell; 2015 Feb; 27(2):271-85. PubMed ID: 25640402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer.
    Chu PY; Hou MF; Lai JC; Chen LF; Lin CS
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Versatile In Vivo System to Study Myc in Cell Reprogramming.
    Senís E; Mosteiro L; Grimm D; Abad M
    Methods Mol Biol; 2021; 2318():267-279. PubMed ID: 34019296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
    Xiao JF; Sun QY; Ding LW; Chien W; Liu XY; Mayakonda A; Jiang YY; Loh XY; Ran XB; Doan NB; Castor B; Chia D; Said JW; Tan KT; Yang H; Fu XY; Lin DC; Koeffler HP
    J Pathol; 2018 Sep; 246(1):89-102. PubMed ID: 29926931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.